Across TCGA pan-cancer cohorts, DPH5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DPH5 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DPH5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DPH5 expression acts as an unfavorable survival marker.
BLCA are the cancer types where DPH5 Mutation most reproducibly stratifies survival.